Dilrini De Silva1,2,3, Joanna Peters4, John Paul2,5,6, David W Eyre1,2,3, Kevin Cole5,6, Michelle J Cole7, Fiona Cresswell5, Gillian Dean5, Jayshree Dave6, Daniel Rh Thomas8, Kirsty Foster9, Alison Waldram10, Daniel J Wilson1,2, Xavier Didelot11, Yonatan H Grad12, Derrick W Crook1,2,3,6, Tim Ea Peto1,2,3, A Sarah Walker1,2,3. 1. Nuffield Department of Medicine, University of Oxford, Oxford, UK. 2. National Institute for Health Research Biomedical Research Centre, Oxford, UK. 3. Oxford National Institute for Health Research Health Protection Research Unit. 4. St George's University Hospitals NHS Foundation Trust, London, UK. 5. Brighton and Sussex University Hospitals NHS Trust, Brighton, UK. 6. National Infection Service, Public Health England, UK. 7. Public Health England Sexually Transmitted Bacterial Reference Unit, Colindale, London, UK. 8. Communicable Disease Surveillance Centre, Public Health Wales, Cardiff, UK. 9. Health Protection Team, Public Health England North East, UK. 10. Field Epidemiology Service Newcastle, Public Health England, Newcastle upon Tyne, UK. 11. Department of Infectious Disease Epidemiology, Imperial College, London, UK. 12. Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, and Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA, USA.
Abstract
BACKGROUND: New approaches are urgently required to address increasing rates of gonorrhoea and the emergence and global spread of antibiotic-resistant Neisseria gonorrhoeae. We used whole-genome sequencing to study transmission and track resistance in N gonorrhoeae isolates. METHODS: We did whole-genome sequencing of isolates obtained from samples collected from patients attending sexual health services in Brighton, UK, between Jan 1, 2011, and March 9, 2015. We also included isolates from other UK locations, historical isolates from Brighton, and previous data from a US study. Samples from symptomatic patients and asymptomatic sexual health screening underwent nucleic acid amplification testing; positive samples and all samples from symptomatic patients were cultured for N gonorrhoeae, and resulting isolates were whole-genome sequenced. Cefixime susceptibility testing was done in selected isolates by agar incorporation, and we used sequence data to determine multi-antigen sequence types and penA genotypes. We derived a transmission nomogram to determine the plausibility of direct or indirect transmission between any two cases depending on the time between samples: estimated mutation rates, plus diversity noted within patients across anatomical sites and probable transmission pairs, were used to fit a coalescent model to determine the number of single nucleotide polymorphisms expected. FINDINGS: 1407 (98%) of 1437 Brighton isolates between Jan 1, 2011, and March 9, 2015 were successfully sequenced. We identified 1061 infections from 907 patients. 281 (26%) of these infections were indistinguishable (ie, differed by zero single nucleotide polymorphisms) from one or more previous cases, and 786 (74%) had evidence of a sampled direct or indirect Brighton source. We observed multiple related samples across geographical locations. Of 1273 infections in Brighton (including historical data), 225 (18%) were linked to another case elsewhere in the UK, and 115 (9%) to a case in the USA. Four lineages initially identified in Brighton could be linked to 70 USA sequences, including 61 from a lineage carrying the mosaic penA XXXIV allele, which is associated with reduced cefixime susceptibility. INTERPRETATION: We present a whole-genome-sequencing-based tool for genomic contact tracing of N gonorrhoeae and demonstrate local, national, and international transmission. Whole-genome sequencing can be applied across geographical boundaries to investigate gonorrhoea transmission and to track antimicrobial resistance. FUNDING: Oxford National Institute for Health Research Health Protection Research Unit and Biomedical Research Centre.
BACKGROUND: New approaches are urgently required to address increasing rates of gonorrhoea and the emergence and global spread of antibiotic-resistant Neisseria gonorrhoeae. We used whole-genome sequencing to study transmission and track resistance in N gonorrhoeae isolates. METHODS: We did whole-genome sequencing of isolates obtained from samples collected from patients attending sexual health services in Brighton, UK, between Jan 1, 2011, and March 9, 2015. We also included isolates from other UK locations, historical isolates from Brighton, and previous data from a US study. Samples from symptomatic patients and asymptomatic sexual health screening underwent nucleic acid amplification testing; positive samples and all samples from symptomatic patients were cultured for N gonorrhoeae, and resulting isolates were whole-genome sequenced. Cefixime susceptibility testing was done in selected isolates by agar incorporation, and we used sequence data to determine multi-antigen sequence types and penA genotypes. We derived a transmission nomogram to determine the plausibility of direct or indirect transmission between any two cases depending on the time between samples: estimated mutation rates, plus diversity noted within patients across anatomical sites and probable transmission pairs, were used to fit a coalescent model to determine the number of single nucleotide polymorphisms expected. FINDINGS: 1407 (98%) of 1437 Brighton isolates between Jan 1, 2011, and March 9, 2015 were successfully sequenced. We identified 1061 infections from 907 patients. 281 (26%) of these infections were indistinguishable (ie, differed by zero single nucleotide polymorphisms) from one or more previous cases, and 786 (74%) had evidence of a sampled direct or indirect Brighton source. We observed multiple related samples across geographical locations. Of 1273 infections in Brighton (including historical data), 225 (18%) were linked to another case elsewhere in the UK, and 115 (9%) to a case in the USA. Four lineages initially identified in Brighton could be linked to 70 USA sequences, including 61 from a lineage carrying the mosaic penA XXXIV allele, which is associated with reduced cefixime susceptibility. INTERPRETATION: We present a whole-genome-sequencing-based tool for genomic contact tracing of N gonorrhoeae and demonstrate local, national, and international transmission. Whole-genome sequencing can be applied across geographical boundaries to investigate gonorrhoea transmission and to track antimicrobial resistance. FUNDING: Oxford National Institute for Health Research Health Protection Research Unit and Biomedical Research Centre.
Authors: Eline L Korenromp; Mondastri K Sudaryo; Sake J de Vlas; Ronald H Gray; Nelson K Sewankambo; David Serwadda; Maria J Wawer; J Dik F Habbema Journal: Int J STD AIDS Date: 2002-02 Impact factor: 1.359
Authors: K Foster; M Cole; O Hotonu; J Stonebridge; G Hughes; I Simms; C Ison; A Waldram Journal: Sex Transm Infect Date: 2016-03-02 Impact factor: 3.519
Authors: David Hess; Abel Wu; Daniel Golparian; Sarah Esmaili; Will Pandori; Emilee Sena; Jeffrey D Klausner; Pennan Barry; Magnus Unemo; Mark Pandori Journal: Antimicrob Agents Chemother Date: 2012-08-20 Impact factor: 5.191
Authors: Walter Demczuk; Irene Martin; Shelley Peterson; Amrita Bharat; Gary Van Domselaar; Morag Graham; Brigitte Lefebvre; Vanessa Allen; Linda Hoang; Greg Tyrrell; Greg Horsman; John Wylie; David Haldane; Chris Archibald; Tom Wong; Magnus Unemo; Michael R Mulvey Journal: J Clin Microbiol Date: 2016-03-02 Impact factor: 5.948
Authors: Mark Pandori; Pennan M Barry; Abel Wu; Alyssa Ren; William L H Whittington; Sally Liska; Jeffrey D Klausner Journal: Antimicrob Agents Chemother Date: 2009-06-22 Impact factor: 5.191
Authors: Benjamin Schubert; Rohan Maddamsetti; Jackson Nyman; Maha R Farhat; Debora S Marks Journal: Nat Microbiol Date: 2018-12-03 Impact factor: 17.745
Authors: Brian Arnold; Mashaal Sohail; Crista Wadsworth; Jukka Corander; William P Hanage; Shamil Sunyaev; Yonatan H Grad Journal: Mol Biol Evol Date: 2020-02-01 Impact factor: 16.240
Authors: David W Eyre; Dilrini De Silva; Kevin Cole; Joanna Peters; Michelle J Cole; Yonatan H Grad; Walter Demczuk; Irene Martin; Michael R Mulvey; Derrick W Crook; A Sarah Walker; Tim E A Peto; John Paul Journal: J Antimicrob Chemother Date: 2017-07-01 Impact factor: 5.790
Authors: Liteboho D Maduna; Marleen M Kock; Brian M J W van der Veer; Oscar Radebe; James McIntyre; Lieke B van Alphen; Remco P H Peters Journal: Antimicrob Agents Chemother Date: 2020-10-20 Impact factor: 5.191